vimarsana.com
Home
Live Updates
MHRA approves biosimilar for vision disorders in Great Brita
MHRA approves biosimilar for vision disorders in Great Brita
MHRA approves biosimilar for vision disorders in Great Britain
A marketing authorization for Ximluci® biosimilar referencing Lucentis® (ranibizumab) in Great Britain has been issued by the MHRA.
Related Keywords
Norway ,
Iceland ,
Liechtenstein ,
United Kingdom ,
Great Britain ,
British ,
Bryan Kim ,
Genus Pharmaceuticals ,
European Union ,
European Medicines Agency ,
European Commission Ec Decision Reliance Procedure ,
Regulatory Agency ,
European Commission ,
Decision Reliance Procedure ,
Middle East ,
North Africa ,